Nine Square Therapeutics
Even well-funded platform biotechs targeting scientifically validated but historically undruggable targets can run out of runway if they cannot translate discovery into a compelling near-term catalyst.
Nine Square Therapeutics was a Biotechnology and Pharmaceutical startup founded in 2020 in USA. It raised $55 million before collapsing in 2026 — 6 years of runway burned. IdeaProof's AI Failure Score: 7/100, driven by liquidity crisis, funding standstill. The shutdown affected employees, investors, and the broader Biotechnology and Pharmaceutical ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Nine Square Therapeutics fail?
Nine Square Therapeutics failed in 2026 after 6 years of operation, losing $55 million in raised capital. The root cause was liquidity crisis, funding standstill. Key lesson: Even well-funded platform biotechs targeting scientifically validated but historically undruggable targets can run out of runway if they cannot translate discovery into a compelling near-term catalyst.
2020 → 2026
$55 million
Biotechnology and Pharmaceutical
USA
IdeaProof AI Failure Score
What Happened: The Timeline
2020
Nine Square founded
2022
Last funding round of $4.5m
2026-01
Chapter 11 bankruptcy filed in Delaware
Root Causes
Nine Square Therapeutics was a Boston-area biotech founded in 2020, focused on developing therapies for neurodegenerative diseases by targeting autophagy to address genetically validated but historically undruggable targets. The company used machine-learning-enabled cell profiling and secured funding from ATP, The Michael J. Fox Foundation, and venture investors, raising ~$54.5 million total, with its last funding round of $4.5 million about three years prior to closure. Nine Square filed for Chapter 11 bankruptcy protection in the Delaware Bankruptcy Court, with the case filed on January 1, 2026. The bankruptcy adds to a broader wave of biotech shutdowns in 2025-2026 as venture funding tightened.
Causal Chain
This is our reading of the causal chain — separated from the verifiable facts above. Timeline dates, funding numbers and filings are facts (see methodology); root / proximate / terminal attribution is judgement based on public evidence.
A combination of demand-side, execution, and capital-market pressures that this record documents without isolating a single dominant driver.
- Failure to advance pipeline candidates to a stage attracting further institutional investment
- Depleted cash reserves after $54.5 million raised without a late-stage clinical or partnership win
- Challenging biotech funding environment for early-stage neurodegenerative disease programs
- Reliance on niche machine-learning-enabled autophagy platform without near-term commercial catalyst
2026: cessation of operations after failing to secure additional capital or a strategic buyer.
Base rates
A single failure is an anecdote. These base rates give you the denominator — how common this outcome is across all startups matching Nine Square Therapeutics's profile. Sources are third-party; we do not restate them as our own claims.
of venture-backed consumer hardware startups do not reach a profitable exit within 10 years — hardware requires atypical capital efficiency to survive.
PitchBook Emerging Tech Research (2023)of digital-health startups fail to reach breakeven; reimbursement complexity + regulatory approvals extend runway needs beyond typical VC horizons.
Rock Health State of Digital Health (2023)of startups ultimately fail — including ~10% that fail in the first year and the rest across the following decade.
Startup Genome / CB Insights aggregate (2024)of new US employer businesses survive past their 10th year (Bureau of Labor Statistics BED series).
US Bureau of Labor Statistics — BED (2024)of Series A rounds ever graduate to Series B; the rest run out of runway or pivot without a follow-on.
CB Insights Venture Capital Funnel (2023)Key Lessons Learned
2. Depleted cash reserves after $54.5 million raised without a late-stage clinical or partnership win
Depleted cash reserves after $54.5 million raised without a late-stage clinical or partnership win — a recurring pattern across biotechnology and pharmaceutical failures. Validate this risk before you scale.
Frequently Asked Questions
Sources & Confidence
Every data point is tagged with its source type and our confidence in it. How we grade sources.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Nine Square Therapeutics.
Spotted a factual error?
Approved corrections are published in the public changelog with attribution.